Nancy Thornberry

Ms. Thornberry currently serves as the Chief Executive Officer of Kallyope, a platform biotechnology company focused on identifying and pursuing therapeutic opportunities involving the gut-brain axis. In addition to her role at Kallyope, she serves as a Director at Intarcia Therapeutics. Prior to joining Kallyope, Ms. Thornberry served in roles of increasing responsibility at Merck & Co, Inc., including as Senior Vice President and Franchise Head, Diabetes and Endocrinology. In this role, Ms. Thornberry led discovery and clinical research across several therapeutic areas, including diabetes, osteoporosis, fertility, and contraception. During her career at Merck, Ms. Thornberry initiated and led multiple drug discovery and development programs, including Merck’s dipeptidyl peptidase 4 (DPP-4) inhibitor (marketed as JANUVIA®) for the treatment of Type 2 diabetes.